Clinical Indication

Treating primary hypercholesterolaemia or mixed dyslipidaemia. SECONDARY PREVENTION ONLY as per NICE TA733


For prescribers who feel competent to use this medication.

In line with NICE TA733.

For further related guidance please see the Cardiovascular Guidelines page. This page also includes an interim inclisiran pathway.


Date of classification

February 2022


Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.